BioArctic AB
OTC:BRCTF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
BioArctic AB (BRCTF) under the Base Case is 19.2 USD per share.
Compared with the current market price of 30.1 USD, the stock appears
Overvalued by 36% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What BioArctic AB Does
BioArctic is a Swedish drug company focused on treatments for neurodegenerative diseases, especially Alzheimer’s disease and Parkinson’s disease. It does not run a broad consumer business; instead, it discovers and develops medicines and then partners with larger pharmaceutical companies to test, manufacture, and sell them. Its best-known work is around antibody-based drugs that target harmful proteins in the brain.
- Headquarters
- Sweden SE
- Employees
- 49
- IPO date
- Oct 12, 2017
Balance Sheet
Continue BRCTF Research
Decided on BioArctic? Get an email when BRCTF reaches the price you’d buy at. Free with an account.
Other BioArctic listings
What is the Intrinsic Value of one BRCTF stock?
The intrinsic value for
BioArctic AB (BRCTF) under the Base Case is 19.2 USD.
Is BRCTF stock undervalued or overvalued?
Compared with the current market price of 30.1 USD, the stock appears Overvalued by 36% .